Investors & MediaVectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies that have the potential to meaningfully transform and improve the lives of patients.
Recent News and Upcoming Events
Jun 29, 2022
VectivBio Announces Closing of $54 Million Aggregate Financing
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of